{"Clinical Trial ID": "NCT00171704", "Intervention": ["INTERVENTION 1:", "- Letrozole", "2.5 mg once daily (q.d.) or for 5 years", "INTERVENTION 2:", "Tam-Let", "20 mg Tamoxifene once daily (q.d.) orally for 2 years followed by Letrozole 2.5 mg q.d. orally for 3 years."], "Eligibility": ["\u2022 Inclusion criteria", "Women", "The postmenopausal hormonal status is defined as follows:", "Patients with menostasis (menorrhoea) > 12 months or a history of oophorectomy.", "Patients 55 years of age with a history of hysterectomy or who have continued/renewed menstruation on cyclic hormone therapy.", "Patients aged 50 to 54 years: Menopausal status was determined on the basis of folliculo-stimulating hormone (FSH)/luteinizing hormone (LH) values.", "At a minimum, patients should have positive receptor tumours, which were defined either as estrogen receptor (ER) and/or progesterone receptor (PgR) 10 fmol/mg cytosol protein; or 10% of positive tumour cells by immunocytochemical evaluation.", "Adequate bone marrow function (number of white blood cells [WBC] > 3.0 x 109/L, platelets 100.0 x 109/L and hemoglobin > 10 g/dL).", "Documented evidence of adequate renal function (creatinine < 180 \u03bcmol/L) and hepatic function (bilirubin < 30 \u03bcmol/L, alanine aminotransferase (ALT) < 1.5 x upper normal laboratory limit).", "\u2022 Life expectancy of at least 24 months at the time of registration.", "Informed consent in writing prior to the commencement of any study procedure.", "The willingness to undergo all the tests and examinations planned for the assessment of bone density and bone metabolism, as well as lipid profiles, in addition to the standard assessments for the monitoring of their breast cancer status.", "\u2022 Exclusion criteria", "* Patients with remote metastases as defined by the criteria of the Danish Cooperative Breast Cancer Group (DBCCOG).", "A pre-existing bone disease (e.g. osteomalacia, imperfect osteogenesis, Paget's disease).", "Patients receiving bisphosphonates for more than 3 months prior to randomization.", "- Chronic treatment with medicines known to interfere with bone metabolism, e.g.", "- Anticonvulsants in the past year.", "The corticosteroids at doses greater than the equivalent of 5 mg/day of prednisone for more than two weeks in the last 6 months (before randomization).", "Any previous treatment with sodium fluoride at daily doses of 5 mg/day for a period of more than 1 month.", "The anabolic steroids in the last 12 months.", "The long-term use of coumarin and heparin derivatives at the time of randomization.", "- Metabolic diseases known to interfere with bone metabolism (e.g., hyperparathyroidism, hypoparathyroidism, uncontrolled thyroid disease, Cushing's disease, vitamin D deficiency, malabsorption syndrome, etc.).", "Treatment with hypolipids within 3 months prior to randomisation (this exclusion criterion did not apply to patients randomised in the United Kingdom).", "Patients receiving another anticancer treatment.", "- Neoadjuvant/adjuvant chemotherapy and/or previous adjuvant endocrine therapy (e.g., anti-estrogen, anti-AI).", "Patients with endometrial cancer and/or invasive breast cancer at any time in their medical history were excluded. Patients with invasive bilateral breast cancer were excluded. Patients with vaginal discharge/ vaginal bleeding with signs of malignancy were excluded.", "Any other non-malignant systemic disease (heart, kidney, liver, pulmonary embolism, etc.) that would prevent prolonged follow-up."], "Results": ["Performance measures:", "Percentage change from baseline in bone mineral density of the lumbar spine (L2-4)", "The primary scan site was the lumbar column (L2 to L4) and the secondary scan site was the total hip.", "Target date: Baseline, 24 months", "Results 1:", "Title of the arm/group: Letrozole", "Description of the arm/group: 2.5 mg once daily (q.d.) or for 5 years", "Total number of participants analysed: 63", "Median (full range)", "Unit of measure: Percentage change -4.63 (-14.21 to 4.32)", "Results 2:", "Title of the arm/group: Tam-Let", "Description of the arm/group: 20 mg Tamoxifene once daily (q.d.) orally for 2 years followed by Letrozole 2.5 mg q.d. orally for 3 years.", "Total number of participants analysed: 68", "Median (full range)", "Unit of measure: Percentage change 0.37 (-6.98 to 15.21)"], "Adverse Events": ["Undesirable Events 1:", "Total: 50/133 (37.59 per cent)", "- Acute myocardial infarction 0/133 (0.00 %)", "Angine pectoris 1/133 (0.75%)", "Unstable Angina 0/133 (0.00 %)", "Arrhythmia 1/133 (0.75%)", "Atrial affiliation 2/133 (1.50%)", "Atrial flutter rate 0.133 (0.00 %)", "1/133 (0.75%)", "Myocardial infarction 0/133 (0.00 per cent)", "Pericarditis 0/133 (0.00 %)", "Sinus bradycardia 0/133 (0.00 %)", "Adverse Events 2:", "Total: 41/130 (31.54 per cent)", "- Acute myocardial infarction 2/130 (1.54%)", "Angine pectoris 1/130 (0.77%)", "Unstable Angina 1/130 (0.77%)", "Arrhythmia 0/130 (0.00 %)", "Atrial fibrillation 2/130 (1.54%)", "Atrial flute 1/130 (0.77%)", "- Left branch block 0/130 (0.00 %)", "Myocardial infarction 1/130 (0.77%)", "Pericarditis 1/130 (0.77%)", "Sinus bradycardia 1/130 (0.77%)"]}